巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Halozyme Therapeutics

    HALO
    48.270
    1.650
    3.54%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Halozyme Therapeutics - 延遲價格・最後更新於 27/05 12:14
    最高位
    48.320
    最低位
    46.520
    開市價
    --
    前收市價
    46.620
    成交量(千)
    58.03
    成交額(百萬)
    23.40
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    6,658.83
    市盈率
    16.200
    息率
    --
    差價
    --
    52週高低
    48.340 - 31.360
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Halozyme Therapeutics
    證券代碼
    HALO.US
    所屬板塊
    Biotechnology
    公司業務
    Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
    發行量
    137703510
    公司總部
    11388 Sorrento Valley Road
    公司網址
    https://www.halozyme.com
    公司電郵
    ir@halozyme.com
    公司電話
    +1 858 794-8889

    美股異動 | 安塔爾製藥(ATRS.US)漲近50% 奧洛茲美醫療將以每股5.6美元收購

    格隆匯·
    美股異動 | 安塔爾製藥(ATRS.US)漲近50% 奧洛茲美醫療將以每股5.6美元收購

    美股異動 | 安塔爾製藥(ATRS.US)漲近50% 奧洛茲美醫療將以每股5.6美元收購

    格隆匯·
    美股異動 | 安塔爾製藥(ATRS.US)漲近50% 奧洛茲美醫療將以每股5.6美元收購

    格隆匯快訊

    格隆匯··精選
    格隆匯快訊

    關於

    Halozyme Therapeutics(HALO.US)所屬的行業板塊為Biotechnology。
    Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
    詳細公司背景可參考: https://www.halozyme.com